{"id":"intra-nasal-fentanyl","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fentanyl is a synthetic opioid that crosses the blood-brain barrier and activates mu-opioid receptors, which modulate pain perception and emotional responses to pain. The intranasal formulation allows rapid absorption through the nasal mucosa, providing faster onset compared to oral administration, making it suitable for acute pain management and breakthrough pain in opioid-tolerant patients.","oneSentence":"Intra-nasal fentanyl is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to rapidly produce analgesia and sedation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:21.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breakthrough pain in opioid-tolerant patients with cancer"},{"name":"Acute pain management"}]},"trialDetails":[{"nctId":"NCT07148882","phase":"PHASE2, PHASE3","title":"Pain Managment in Preterm Neonates","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-02-01","conditions":"Preterm Neonates Pain Managment, PreTerm Neonate","enrollment":52},{"nctId":"NCT02095366","phase":"PHASE4","title":"Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2013-08-02","conditions":"Severe Traumatic Pain, Numeric Pain Rating Scale > 5 / 10","enrollment":194},{"nctId":"NCT04076748","phase":"PHASE3","title":"Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults.","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-20","conditions":"Sickle Cell Crisis","enrollment":196},{"nctId":"NCT01012999","phase":"PHASE1, PHASE2","title":"A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain","status":"TERMINATED","sponsor":"University of Utah","startDate":"2009-11","conditions":"Pain, Opiate","enrollment":16},{"nctId":"NCT00882960","phase":"PHASE4","title":"Intranasal Fentanyl for Pain Management","status":"UNKNOWN","sponsor":"Genesys","startDate":"2009-04","conditions":"Trauma, Pain","enrollment":500},{"nctId":"NCT00654329","phase":"PHASE4","title":"Dexmedetomidine vs Fentanyl for BMT","status":"COMPLETED","sponsor":"Children's National Research Institute","startDate":"2005-08","conditions":"Otitis","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"intra-nasal fentanyl","genericName":"intra-nasal fentanyl","companyName":"Genesys","companyId":"genesys","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intra-nasal fentanyl is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to rapidly produce analgesia and sedation. Used for Breakthrough pain in opioid-tolerant patients with cancer, Acute pain management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}